GlassScriptPhysician profile
Amy Katheryn Case
NPI 1033549076
$7,977.45
in general payments reported to CMS, 2019-2025
41 companies · $1,278 in 2025
The $1,278 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $946 · 2022: $1,446 · 2023: $1,455 · 2024: $2,852 · 2025: $1,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,414 · Travel and Lodging: $1,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,413.50 |
| Travel and Lodging | $1,171.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,870.44 | 2022-2025 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $1,141.30 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $567.39 | 2021-2025 | |
| Amgen INC. | $541.24 | 2021-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $479.50 | 2021-2025 | Ozempic, Rybelsus, Saxenda |
| Lilly USA, LLC | $378.02 | 2021-2025 | Mounjaro, Emgality, Reyvow |
| Bayer Healthcare Pharmaceuticals INC. | $328.31 | 2021-2025 | |
| Glaxosmithkline, LLC. | $291.13 | 2021-2025 | Trelegy Ellipta, Arexvy, Boostrix |
| Novartis Pharmaceuticals Corporation | $273.12 | 2022-2025 | Leqvio |
| Sanofi-Aventis U.S. LLC | $235.50 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $201.15 | 2021-2024 | Xarelto |
| Lundbeck LLC | $182.10 | 2021-2024 | Vyepti |
| Dexcom, INC. | $153.02 | 2021-2025 | Dexcom G6 Transmitter |
| Camber Spine Technologies LLC | $139.25 | 2022 | |
| Pfizer INC. | $122.32 | 2023-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Case listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.